Polycystic ovary syndrome (PCOS) has multiple etiologies including ovarian and adrenal
hyperandrogenism, neuro-endocrine and hypothalamic-pituitary dysfunction, and disorders …

BACKGROUND Hirsutism, defined by the presence of excessive terminal hair in androgen-
sensitive areas of the female body, is one of the most common disorders in women during …

Background Polycystic ovary syndrome (PCOS) is characterised by infrequent or absent
ovulation, and high levels of androgens and insulin (hyperinsulinaemia). Hyperinsulinaemia …

Polycystic ovary syndrome (PCOS) is recognized as the most common endocrine disorder of
reproductive-aged women around the world. This document, produced by the collaboration …

Polycystic ovary syndrome (PCOS), a relevant cause of infertility, is a heterogeneous,
endocrine disorder affecting up to 10–15% of women in reproductive age. Besides …

Background Polycystic ovary syndrome (PCOS) has a prevalence of 8%‐13%. Given the
prevalence, diverse health impacts and variation in care, rigorous evidence‐based …

Polycystic ovary syndrome (PCOS) encompasses an ovarian and a metabolic dysfunction.
Glucagon-like peptide-1 (GLP-1) analogues facilitate weight loss and ameliorate metabolic …

Background Metformin has been proposed as possibly a safer and more effective long‐term
treatment than the oral contraceptive pill (OCP) in women with polycystic ovary syndrome …

Context: Polycystic ovary syndrome (PCOS) is common among women of childbearing age
and the available pharmacological therapies have different side-effect profiles. Objective …

Purpose To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI)
on adiponectin levels and metabolic characteristics in women with polycystic ovary …